Amoytop Acquires Skyline To Kickstart China 2025 M&A Activity

 
• By Dexter Jie Yan

Shanghai-listed Amoytop will take over the non-US operations of Skyline Therapeutics for $58m in total potential payments, in a deal revealing Amoytop’s ambitions to muscle into the gene therapy field.

Xiamen Amoytop Biotech has announced the first acquisition between Chinese biopharmas and pre-revenue biotechs in years. (Shutterstock)

More from China

More from Business